(Q37808612)

23 August 2017

An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction (English)

1 reference

23 August 2017

Victor Palit

1

1 reference

PubMed ID

21068761

23 August 2017

Ian Eardley

series ordinal

2

1 reference

PubMed ID

21068761

23 August 2017

language of work or name

English

0 references

publication date

1 November 2010

1 reference

23 August 2017

Nature Reviews Urology

1 reference

23 August 2017

7

1 reference

23 August 2017

603-609

1 reference

23 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2010.165

23 August 2017

0 references

cites work

Cyclic GMP phosphodiesterase-5: target of sildenafil

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Pharmacotherapy for erectile dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Mechanism of erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

A role for the melanocortin 4 receptor in sexual function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

The application of gene therapy to the treatment of erectile dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Gene therapy for erectile dysfunction: fact or fiction?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Superoxide dismutase - a target for gene therapeutic approach to reduce oxidative stress in erectile dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Oxidative stress and neurodegeneration in penile ischaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Gene transfer of vasoactive intestinal polypeptide into the penis improves erectile response in the diabetic rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Gene transfer of prepro-calcitonin gene-related peptide restores erectile function in the aged rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Molecular pathophysiology and gene therapy of aging-related erectile dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Effect of muscle-derived stem cells on the restoration of corpora cavernosa smooth muscle and erectile function in the aged rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.165

Pharmacology of phosphodiesterase-5 inhibitors.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21068761

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Plasmid-based gene transfer for treatment of erectile dysfunction and overactive bladder: results of a phase I trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21068761

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRUROL.2010.165

1 reference

23 August 2017

1 reference

PubMed ID

21068761